NAS
RARE icon

Nykredit A/S’s Ultragenyx Pharmaceutical RARE Stock Holding History

Nykredit A/S’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Buy
+4,615
New +$115K ﹤0.01% 1145

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nykredit A/S's RARE Position: Q2 2026 in Review

Nykredit A/S opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 4,615 shares worth $154K. The stake represents ﹤0.01% of the portfolio and ranks #1145 among its holdings.

206 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Nykredit A/S held 4,615 shares of Ultragenyx Pharmaceutical worth $154K as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new Nykredit A/S position in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1145 holding.
  • 206 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.